[go: up one dir, main page]

AR134544A1 - Pharmaceutical combinations for use in the treatment of fungal infections - Google Patents

Pharmaceutical combinations for use in the treatment of fungal infections

Info

Publication number
AR134544A1
AR134544A1 ARP240103302A ARP240103302A AR134544A1 AR 134544 A1 AR134544 A1 AR 134544A1 AR P240103302 A ARP240103302 A AR P240103302A AR P240103302 A ARP240103302 A AR P240103302A AR 134544 A1 AR134544 A1 AR 134544A1
Authority
AR
Argentina
Prior art keywords
treatment
fungal infections
pharmaceutical combinations
combinations
pharmaceutically acceptable
Prior art date
Application number
ARP240103302A
Other languages
Spanish (es)
Inventor
Marc Engelhardt
Laurenz Kellenberger
Karine Litherland
Original Assignee
Basilea Pharmaceutica Int Ag Allschwil
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basilea Pharmaceutica Int Ag Allschwil filed Critical Basilea Pharmaceutica Int Ag Allschwil
Publication of AR134544A1 publication Critical patent/AR134544A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona combinaciones que comprenden (a) un compuesto de fórmula (1) en donde M(III) es un ión seleccionado de Al, Fe y Ga; o una sal farmacéuticamente aceptable del mismo, y (b) un agente antifúngico a base de triazol o una sal farmacéuticamente aceptable del mismo, así como también métodos para utilizar las combinaciones en la prevención y en el tratamiento de infecciones fúngicas.The present invention provides combinations comprising (a) a compound of formula (1) wherein M(III) is an ion selected from Al, Fe and Ga; or a pharmaceutically acceptable salt thereof, and (b) a triazole-based antifungal agent or a pharmaceutically acceptable salt thereof, as well as methods for using the combinations in the prevention and treatment of fungal infections.

ARP240103302A 2023-11-30 2024-12-02 Pharmaceutical combinations for use in the treatment of fungal infections AR134544A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP23213359 2023-11-30

Publications (1)

Publication Number Publication Date
AR134544A1 true AR134544A1 (en) 2026-01-28

Family

ID=89030024

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240103302A AR134544A1 (en) 2023-11-30 2024-12-02 Pharmaceutical combinations for use in the treatment of fungal infections

Country Status (3)

Country Link
AR (1) AR134544A1 (en)
TW (1) TW202541814A (en)
WO (1) WO2025114603A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045008A1 (en) 1998-03-06 1999-09-10 F. Hoffmann-La Roche Ag 3-[4-(4-cyanophenyl)thiazol-2-y)]-1-(1h-1,2,4-triazol-1-yl)-butan-2-ol derivatives having antifungal activity
DE60018989T2 (en) 1999-11-02 2005-08-18 Basilea Pharmaceutica Ag N-CARBAMOYLOXYALKYL SUBSTITUTED AZOLIUM COMPOUNDS
KR101493546B1 (en) 2007-08-21 2015-02-16 바실리어 파마슈티카 아게 Antifungal composition
ES2464723T3 (en) 2008-03-14 2014-06-03 Astellas Pharma Inc. Cyclic compound and salt thereof
EP2261317B8 (en) 2008-03-14 2014-04-23 Astellas Pharma Inc. Microorganism producing cyclic compound
PL3227277T3 (en) 2014-12-05 2020-08-10 Pulmocide Limited Antimycotic compound

Also Published As

Publication number Publication date
TW202541814A (en) 2025-11-01
WO2025114603A1 (en) 2025-06-05

Similar Documents

Publication Publication Date Title
DOP2022000124A (en) PYRAZOLIL DERIVATIVES USEFUL AS ANTICANCER AGENTS
AR112271A1 (en) COMPOSITIONS INCLUDING AN INHIBITOR OF RNA POLYMERASE AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
MX2022000271A (en) Hpk1 inhibitors and uses thereof.
MX2024002538A (en) Use of ezh2 inhibitor in preparation of drug for treating t-cell lymphoma.
CL2021002217A1 (en) Pharmaceutical composition comprising a flt3 inhibitor and a hypomethylating agent to treat acute myeloid leukemia
AR121598A1 (en) OXAZOLIDINONE COMPOUND AND METHODS OF USE OF IT AS AN ANTIBACTERIAL AGENT
CO2022016153A2 (en) il4i1 inhibitors and methods of use
MX2018014080A (en) USE OF CARBAMATE COMPOUND TO PREVENT OR TREAT FIBROMIALGIA OR FUNCTIONAL SYNDROME ASSOCIATED WITH FIBROMIALGIA.
MX2024002581A (en) LOU064 FOR THE TREATMENT OF MULTIPLE SCLEROSIS.
AR034854A1 (en) COMPOUND OF CONDENSED IMIDAZOL, DRUG OF THE SAME, PHARMACEUTICAL COMPOSITION AND AGENT TO REDUCE ANDROGENS CONTAINING IT, METHOD TO PRODUCE IT, DIASTEREOMERIC SALT OF SUCH COMPOUND AND METHOD TO PRODUCE AN OPTICAL COMPOUND COMPOSITE
MX2025005392A (en) Pharmaceutical composition comprising aak1 inhibitor
MX2020011367A (en) OXO-SUBSTITUTED COMPOUND.
AR130828A1 (en) METHOD FOR TREATING CANCER
MX2022011240A (en) Immunomodulating urea azalides.
CO2025016753A2 (en) gsk3α inhibitors and methods of their use
CL2023000200A1 (en) New pyrazole derivative
AR134544A1 (en) Pharmaceutical combinations for use in the treatment of fungal infections
CO2025002794A2 (en) Combinations of antineoplastic compounds comprising a bifunctional compound with inhibitory activity against mutant Kras g12d
MX2025002228A (en) Methods for the treatment or prophylaxis of endometriosis
UY39394A (en) PESTICIDE COMPOUNDS AND COMPOSITIONS, METHODS OF USE AND PROCESSES FOR THE PREPARATION OF THE SAME
AR113221A1 (en) ANTIFUNGAL AGENTS USED IN COMBINATION
CO2025002789A2 (en) Combinations of antineoplastic agents comprising a bifunctional compound with inhibitory activity against mutant Kras g12d
MX2018014081A (en) USE OF CARBAMATE COMPOUND TO PREVENT OR TREAT TRIGEMINAL NEURALGIA.
AR131842A1 (en) METHODS FOR TREATING GLIOMAS
BR112023026356A2 (en) METHOD FOR TREATING HEPATITIS C VIRUS OR A CONDITION RESULTING FROM A HEPATITIS C INFECTION, COMBINATION, USE OF THE COMBINATION, PHARMACEUTICAL COMPOSITION, AND, KIT FOR TREATMENT OF HEPATITIS C VIRUS